Core Viewpoint - The company,普莱柯, expects a significant increase in net profit for the year 2025, driven by new product launches and growth in the pet sector, despite facing industry challenges [1] Group 1: Financial Performance - The company forecasts a net profit attributable to shareholders of 176 million to 195 million yuan for 2025, representing an increase of 83.19 million to 102 million yuan compared to the previous year [1] - This translates to a year-on-year growth of 89.64% to 110.11% [1] Group 2: Growth Drivers - The introduction of new products, particularly the avian adenovirus series vaccines, has contributed to the company's performance growth [1] - The pet sector has experienced rapid development through continuous efforts in channel building and brand development [1] Group 3: Strategic Focus - In response to intensified industry competition, price pressures, and fluctuations in downstream farming conditions, the company is focusing on marketing system reforms [1] - The company is enhancing control over sales expenses and optimizing production processes and procurement management to further reduce production costs [1] - Overall, the company demonstrates strong operational resilience and aims for high-quality, efficient development [1]

Core Viewpoint - The company, Prike (603566), expects a significant increase in net profit for the year 2025, projecting a range of 176 million to 195 million yuan, which represents a year-on-year growth of 89.64% to 110.11% [1] Group 1 - The launch of new products, such as the avian adenovirus series combined vaccine, has contributed to the company's performance growth [1] - The pet segment has experienced rapid development through continuous efforts in channel building and brand development [1]

Core Viewpoint - The company, Pulaike (603566.SH), forecasts a significant increase in net profit for the year 2025, indicating strong growth driven by new product launches and developments in the pet sector [1] Financial Performance - The company expects a net profit attributable to shareholders of 176 million to 195 million yuan for 2025, representing a year-on-year increase of 89.64% to 110.11% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 137 million to 153 million yuan, reflecting a year-on-year growth of 70.19% to 90.07% [1] Product and Market Development - The launch of new products, particularly the avian adenovirus series vaccines, has contributed to the company's performance growth [1] - The pet segment has experienced rapid development through continuous efforts in channel building and brand enhancement [1]

证券代码：603566 证券简称：普莱柯 公告编号：2026-004 普莱柯生物工程股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 一、本期业绩预告情况 （一）本期业绩预告期间 三、本期业绩预增的主要原因 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告具体情况 1、经公司财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的 净利润为 17,600.00 万元到 19,500.00 万元，与上年同期相比，增加 8,319.35 万元 到 10,219.35 万元，同比上升 89.64%到 110.11%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利润为 13,700.00 万元到 15,300.00 万元，与上年同期相比，增加 5,650.30 万元到 7,250.30 万元，同比上升 70.19%到 90.07%。 2、本次业绩预告为公司初步测算数据，未经审计。 二、上年同期经营业绩和财务状况 （一）归属 ...

Core Viewpoint - The company, Prike (603566.SH), forecasts a significant increase in net profit for the year 2025, driven by new product launches and growth in the pet segment [1] Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between 176 million to 195 million yuan, representing a year-on-year increase of 89.64% to 110.11% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 137 million to 153 million yuan, reflecting a year-on-year growth of 70.19% to 90.07% [1] Product and Market Development - The launch of new products, particularly the avian adenovirus series vaccines, has contributed to the company's performance growth [1] - The pet segment has experienced rapid development through continuous efforts in channel building and brand enhancement [1]

Core Viewpoint - The company expects a significant increase in net profit for 2025, driven by new product launches and strategic marketing efforts [1] Financial Performance - The projected net profit attributable to the parent company for 2025 is estimated to be between 176 million to 195 million yuan, representing a year-on-year increase of 89.64% to 110.11% [1] - The expected net profit after deducting non-recurring gains and losses is forecasted to be between 137 million to 153 million yuan, reflecting a year-on-year growth of 70.19% to 90.07% [1] Business Development - The launch of new products, such as the avian adenovirus series vaccine, has contributed to the company's performance growth [1] - The pet segment has experienced rapid development through continuous efforts in channel building and brand enhancement [1] Strategic Focus - In response to intensified industry competition, price pressures, and fluctuations in downstream farming conditions, the company is focusing on marketing system reform and strengthening sales expense management [1] - The company aims to optimize production processes and procurement management to further reduce production costs, demonstrating strong operational resilience [1]

Core Viewpoint - The company expects a significant increase in net profit for the year 2025, driven by new product launches and effective marketing strategies [1] Financial Performance - The projected net profit attributable to the parent company is estimated to be between 176 million to 195 million yuan, representing a year-on-year increase of 89.64% to 110.11% [1] - The projected non-recurring net profit is estimated to be between 137 million to 153 million yuan, reflecting a year-on-year increase of 70.19% to 90.07% [1] - In the same period last year, the company's net profit attributable to the parent was 92.81 million yuan, and the non-recurring net profit was 80.50 million yuan [1] Business Drivers - The performance increase is primarily attributed to the launch of new products, particularly the avian adenovirus series vaccines, and the positive development in the pet segment [1] - The company is focusing on marketing transformation and cost reduction to enhance efficiency [1]

Market Overview - The animal health sector increased by 3.21% on January 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] Stock Performance - Huisheng Biological (300871) closed at 28.16, up 8.18% with a trading volume of 331,800 shares [1] - Zhongmu Co., Ltd. (600195) closed at 8.49, up 7.88% with a trading volume of 435,600 shares [1] - Other notable performers include: - Biological Co. (600201) at 18.28, up 3.80% [1] - Jinhai Biological (002688) at 6.45, up 3.53% [1] - Shunlian Biological (688098) at 9.91, up 3.23% [1] Capital Flow - The animal health sector saw a net inflow of 175 million yuan from institutional investors, while retail investors experienced a net outflow of 171 million yuan [2] - The main capital flow details include: - Huisheng Biological had a net outflow of 59.49 million yuan from institutional investors [3] - Biological Co. had a net inflow of 58.13 million yuan from institutional investors [3] - Jinhai Biological experienced a net inflow of 35.35 million yuan from institutional investors [3]

Group 1 - The core viewpoint of the article highlights the significant role of AI technology in enhancing the efficiency of key processes in the development of gene-engineered vaccines, such as structural prediction of recombinant proteins, antigen screening, and expression [2] Group 2 - The company, Pulaike, responded to investor inquiries on an interactive platform, emphasizing the importance of AI in vaccine research and development [2]

Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].